Top 7 Reasons Cosmetic Import Applications Get Delayed or Rejected by CDSCO — And How to Avoid Them

Introduction: Why Applications Stall

CliniExperts has managed Cosmetic Import registrations across 30+ countries of origin and 350+ product types. In that experience, the majority of query and application delays are caused by a small, repeatable set of errors — errors that are entirely preventable with a structured pre-submission review.

Reason 1: Inconsistent Product Names or Addresses Across Documents

What CDSCO Sees

Every document in the COS-1 application dossier refers to the same product, the same manufacturer, and the same importer. CDSCO reviewers cross-check the product name, manufacturer name, and manufacturer address across the COS-1 form, the Free Sale Certificate, the Specification Sheet, Formulation, manufacturer authorisation letter, and the product label. Any inconsistency — however minor — triggers a query requesting explanation or corrected documentation.

Common Examples

• Brand name appears as ‘HydraGlow Serum’ on the label but as ‘Hydra Glow Serum’ (with a space) on the Free Sale Certificate
• Manufacturer address includes the postcode on the Manufacturing License but not on the authorization from manufacturer letter
• Company name appears as ‘Cosmetics Corp. Inc.’ on one document and ‘Cosmetics Corporation’ on another

How to Avoid It

Before filing, conduct a document consistency audit: create a comparison table listing the product name, manufacturer name, manufacturer address, and importer name as they appear on each document. 

Reason 2: Non-Cosmetic Claims on the Label

What CDSCO Sees

CDSCO reviewers scrutinise the submitted label for claims that cross the Cosmetic-Drug boundary. A claim that attributes herapeutic, medicinal, or disease-treatment effect to the product cannot appear on a Cosmetic label. When such a claim is present, CDSCO may either request a revised label (adding months to the timeline) or classify the product as a drug — requiring the applicant to withdraw the Cosmetic application and file through the drug approval pathway.

Common Examples

• ‘Clinically proven to reduce wrinkles’ — ‘clinically proven’ implies a Drug-grade study and creates regulatory ambiguity
• ‘Treats acne’ treatment claim; permissible claim would be ‘helps reduce the appearance of blemishes’
• ‘Repairs damaged skin barrier’ ‘repairs’ implies a therapeutic mechanism; ‘supports’ or ‘helps maintain’ are preferred
• ‘Reduces inflammation’ a pharmacological claim

How to Avoid It

Have the India-market label reviewed by a qualified regulatory specialist before it is submitted with the COS-1 application. Develop a brand-specific claims glossary that maps global marketing claims to India-compliant Cosmetic equivalents. This investment protects not just the current application but every future India submission.

Reason 3: Missing or Incomplete Heavy Metal Declaration

What CDSCO Sees

CDSCO requires a product-specific heavy metal declaration confirming that the finished product meets BIS Ninth Schedule limits for lead, arsenic, mercury, and cadmium. Applications that submit only ingredient-level supplier declarations, or that omit the heavy metal declaration entirely, receive a query requesting the finished-product specification sheet with Heavy Metal Tests.

How to Avoid It

Obtain a finished-product heavy metal test report from an ISO/IEC 17025-accredited laboratory before preparing the COS-1 application. Ensure the test report references the product batch number that matches the Certificate of Analysis submitted with the application. Confirm the testing method is referenced to BIS or equivalent international standards.

Reason 4: Incorrect Product Categorisation

What CDSCO Sees

A product assigned to the wrong CDSCO category — or assigned to a single category when it genuinely belongs in two — will receive a categorisation query. The CDSCO reviewer will request justification for the chosen category, a revised COS-1 with the correct category, and sometimes revised supporting documents (particularly if the correct category has different specification requirements).

How to Avoid It

As detailed in Article 3 of this series, conduct a formal categorisation review using the CDSCO-defined category list before preparing the COS-1 application. For borderline products, document the categorisation rationale and include it as a supporting document in the application dossier. Do not rely on the categorisation used in other markets — category definitions differ between India and the EU, US, or ASEAN.

Reason 5: Formulation Does Not Match the Free Sale Certificate

What CDSCO Sees

CDSCO reviewers compare the product formulation submitted in the COS-1 application against the product description in the Free Sale Certificate. Discrepancies arise when the India-application formulation reflects a newer version of the product than the one described on the FSC — a common scenario when products are reformulated between the time the FSC was obtained and the India application is filed.

How to Avoid It

Verify that the formulation version submitted with the India application is precisely the version described in the Free Sale Certificate. If the formulation has changed since the FSC was issued, obtain a new FSC reflecting the current formulation before filing. Do not attempt to file with mismatched versions and explain the discrepancy in a cover letter — CDSCO will request the corrected documents regardless.

Reason 6: BIS Specification Gaps in Test Reports

What CDSCO Sees

Test reports submitted with the application that do not reference BIS Ninth Schedule methods, or that do not cover all specification parameters relevant to the product category, will trigger a query requesting additional or supplementary testing. 

How to Avoid It

When commissioning test reports for the India COS-1 application, provide the testing laboratory with the relevant BIS Ninth Schedule specification requirements for the product category. Confirm that the test methods used are either BIS IS methods or equivalent ISO/AOAC methods that are accepted by CDSCO. 

Reason 7: Incomplete or Invalid Authorisation Chain

What CDSCO Sees

The COS-1 application must include an unbroken authorisation chain from the foreign manufacturer to the entity filing the application in India. CDSCO reviewers check that:

• The authorisation letter is specifically addressed to the named Indian importer or authorised agent
• The authorisation covers the specific product(s) being registered (or the full product range explicitly)
• The authorisation letter is validly executed — signed by an authorised signatory of the manufacturer, with company seal/stamp
• The authorisation is not time-expired at the time of application submission
• The document must be Executed & authenticated either in India format before a First-class Magistrate, or in the country of origin before such an equivalent Authority or attested by the Indian Embassy of the said country or Apostilled from Hague convention member Country.

Common Authorisation Chain Failures

• Authorisation letter issued to a different entity than the one filing the application (e.g., parent company authorisation used by a subsidiary)
• Authorisation covers the product range generally but the specific product names in the application do not match the product range description
• Authorisation letter is more than three to five years old and CDSCO queries whether it remains current

How to Avoid It

Request a specific, current authorisation letter from the manufacturer before preparing the COS-1 application. The letter should name the Indian entity precisely, reference the products by brand name and category, be signed by an identified authorised signatory with their designation, and carry the company seal

The Pre-Submission Checklist: 20 Points Before You File

1. Document consistency audit: product name, manufacturer name, address identical across all documents
2. Label compliance review: no non-Cosmetic, therapeutic, or misleading claims
3. INCI ingredient list on label: complete, in descending order, using INCI nomenclature
4. MRP, country of origin, and importer details on label: Legal Metrology compliant
5. Product categorisation: confirmed against CDSCO category list; borderline cases documented
6. Formulation version: matches Free Sale Certificate exactly
7. Free Sale Certificate: current, issued by competent authority, not expired
8. Certificate of Analysis matches product batch, covers all relevant parameters
9. Heavy metal test report: finished-product specific, ISO/IEC 17025 lab, BIS-method reference
10. Preservative compliance: concentrations declared, BIS limits verified
11. Colourant compliance: all colourants on BIS Ninth Schedule permitted list
12. UV filter compliance (if SPF product): SPF report required as per updated BIS
13. Authorization from Manufacturer: current, specific to Indian entity, covering all products, validly executed
14. Manufacturing site details: complete address, consistent across all documents
15. Fee calculation: category count, variant count, site count verified
16. SUGAM portal: applicant registration complete and active
17. Document language: all documents in English or accompanied by certified translation
18. Novel ingredient check: no ingredient that triggers COS-3/COS-12 pathway in formulation
19. PAC status: no undeclared post-approval changes from previous registrations in the same portfolio
20. Shelf life/best before: correct format, consistent across CoA and label

Key Takeaways

• The top 7 causes of COS-2 delays are: document inconsistency, non-Cosmetic label claims, missing heavy metal declaration, wrong product category, FSC-formulation mismatch, BIS test method gaps, and incomplete authorisation chain
• All seven issues are preventable with a structured pre-submission review — none require reactive remediation
• A 20-point pre-submission checklist, applied consistently, will dramatically reduce deficiency letter rates
• First-time approval (without query) saves an average of 3–6 months on the COS-2 timeline